# Jose M. Galarza

> Jose M. Galarza is the president, CEO and founder of TechnoVax, Inc. Educated at the University of La Plata, he held research appointments in Utah and California before becoming a principal scientist at Wyeth. His career combines invention, technology licensing, scientific authorship and company leadership.

- **Role:** President, CEO and founder at TechnoVax, Inc.
- **Organizations:** TechnoVax, Inc., Wyeth Pharmaceuticals, University of California, Irvine, University of Utah Medical Center, New York Medical College
- **Education:** Doctor of Veterinary Medicine, University of La Plata, Doctorate in Microbiology, University of La Plata, Postdoctoral training in virology and molecular biology, University of Utah Medical Center
- **Known for:** Led the Wyeth team credited with invention of technology subsequently licensed by TechnoVax., Founded and leads TechnoVax, Inc., Named principal investigator on a 2019 Phase II SBIR award of $1,074,853 to TechnoVax.

## Career timeline

- **1977** — Received DVM at the University of La Plata.
- **1981** — Received doctorate in microbiology at the University of La Plata.
- **—** — Held research appointments at the University of Utah Medical Center and University of California, Irvine, before joining Wyeth.
- **—** — Served as principal scientist and research program leader at Wyeth Pharmaceuticals.
- **2003 / 2004** — Galarza’s grant biosketch dates co-founding and becoming CEO to 2003; the company website dates its founding to 2004.
- **2006** — TechnoVax announced licensing of Wyeth technology based on Galarza’s research.
- **2019** — TechnoVax received a MilliporeSigma Advance Biotech Grant; Galarza was also named principal investigator on a Phase II federal award.
- **2021** — TechnoVax identified as Innovative Biotech’s licensor in a Nigeria manufacturing collaboration announcement.
- **2026** — Co-authored a PNAS paper published online June 16.

## Achievements

- Led the Wyeth team credited with invention of technology subsequently licensed by TechnoVax.
- Founded and leads TechnoVax, Inc.
- Named principal investigator on a 2019 Phase II SBIR award of $1,074,853 to TechnoVax.
- Represented TechnoVax among the 2019 North American Advance Biotech Grant recipients.
- Co-authored a 2026 paper in Proceedings of the National Academy of Sciences.

## Latest updates

- **2026-06** — Listed as a TechnoVax-affiliated co-author on a PNAS paper, DOI 10.1073/pnas.2526969123, published online June 16, 2026.

## Links

- Website: https://www.technovax.com/
- LinkedIn: https://www.linkedin.com/in/jose-m-galarza-399a7413

---

Profile page: https://yespress.io/jose-m-galarza
Published by YesPress — https://yespress.io
Last updated: 2026-10-20